# US 2025/0375403 A1 · Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375403 A1
- Document ID: US20250375403A1
- Status: Published application
- Kind: A1
- Application number: 19/073,762
- Filed: 2025-03-07
- Published: 2025-12-11
- Earliest claimed: 2020-03-04
- Assignees: Pleopharma L.L.C.
- Applicants: PleoPharma, Inc.
- Inventors: Ginger D. Constantine
- Web page: https://patentgrep.com/patent/US20250375403A1

## CPC

- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/195: having an amino group
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61P 25/30: for treating abuse or dependence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods of treating cannabis withdrawal syndrome and other cannabis related conditions, including cannabis use disorder, in a subject, comprising administering to the subject in need thereof an effective amount of a cannabinoid or an effective amount of a cannabinoid and an effective amount of a second active agent, such as gabapentin or a gabapentin analog.

## Claims

### Claim 1

A method of treating cannabis withdrawal syndrome, comprising administering to a patient in need thereof about 6 mg of nabilone and a therapeutically effective amount of gabapentin on a daily basis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amount of gabapentin administered is about 200-750 mg per day.

### Claim 3 (depends on 2)

The method of claim 2, wherein the amount of gabapentin administered is about 300-600 mg per day.

### Claim 4 (depends on 3)

The method of claim 3, wherein the treatment results in a reduction in cannabis withdrawal syndrome symptoms as measured by evening cortisol levels, sleep, weight loss, standing heart rate, craving or withdrawal scoring based on the results of one or more questionnaires administered to the subject, withdrawal symptoms based on observations of a health care provider, and combinations thereof.

### Claim 5 (depends on 3)

The method of claim 3, wherein the reduction in symptoms occurs within a time frame following administration of nabilone and gabapentin selected from the group consisting of about 36 hours, about 24 hours, about 18 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, and about 4 hours or less.

### Claim 6 (depends on 3)

The method of claim 3, wherein the daily dose is administered for at least 3 days.

### Claim 7 (depends on 3)

The method of claim 3, wherein the daily dose of nabilone and gabapentin is administered once daily.

### Claim 8 (depends on 3)

The method of claim 3, wherein the reduction in cannabis withdrawal syndrome symptoms comprises a reduction in craving sensations.

### Claim 9 (depends on 3)

The method of claim 3, wherein the reduction in cannabis withdrawal syndrome symptoms comprises a reduction in sleep disturbance and/or an improvement in sleep quality.

### Claim 10 (depends on 3)

The method of claim 3, wherein the treatment results in a reduction in cannabis withdrawal syndrome symptoms as measured by one or more assessment tools selected from the group consisting of WBS score, WBS 6 question subscale score, CWS 6 question subscale score, the Craving subscale, PGI-S, PGI bothersomeness or CGI, wherein the daily dose of nabilone and gabapentin is adjusted in a manner that maintains a withdrawal score on the selected assessment tool to within 150% of the score that is achieved about 24 hours after the first dose of nabilone and gabapentin is administered.

### Claim 11 (depends on 3)

The method of claim 3, wherein the treatment results in a reduction in cannabis withdrawal syndrome symptoms as measured by one or more assessment tools selected from the group consisting of WBS score, WBS 6 question subscale score, CWS 6 question subscale score, the Craving subscale, PGI-S scale, PGI bothersomeness scale or CGI scale, wherein the daily dose of nabilone and gabapentin is adjusted in a manner that maintains a withdrawal score on the selected assessment tool as selective from the group consisting of, a score of 40 or less on the CWS, a score of 25 or less on the CWS 6 question subscale, a score of 20 or less on the WBS, a score of 4 or less on WBS 6 question subscale, a score of 2 or less on the Craving subscale, a score of 1.5 or less on the PGI-S scale, a score of 1.0 or less on the PGI bothersomeness scale or a score of 1.5 or less on the CGI.

### Claim 12

A kit for treating cannabis withdrawal syndrome comprising:
a. a plurality of daily doses of nabilone;
b. a plurality of daily doses of gabapentin; and
c. optionally a dosing schedule for administering the nabilone and gabapentin.

### Claim 13 (depends on 12)

The kit of claim 12, comprising daily doses of nabilone of about 6 mg.

### Claim 14 (depends on 13)

The kit of claim 13, comprising daily doses of gabapentin of about 300-600 mg.
